IL17A and metabolic syndrome: Specifically, IL-17 and chemokines such as CXCR3 enhance the influence of the liver on peripheral insulin resistance by mediating liver inflammation, and promote the occurrence of NAFLD by participating in the process of metabolic syndrome (38–40).